DR. SOURAV KALRA
ASSISTANT PROFESSOR

PUBLICATIONS

• Kumar, S. Kalra, K. Jangid, V. Jaitak, Flavonoids as P-glycoprotein inhibitors for multidrug resistance in cancer: an in-silico approach. Journal of Biomolecular Structure and Dynamics, (2022), 1-13 (accepted)
• S. Mishra, N. Kumar, B.B. Karkara, C.S. Sharma, S. Kalra, Identification of potential inhibitors of Zika virus targeting NS3 helicase using molecular dynamics simulations and DFT studies. Molecular Diversity, (2022) (accepted)
• Shalmali, S. Bawa, M.R. Ali, S. Kalra, R. Kumar, B. Zeya, M.A. Rizvi, A. Husain, Molecular docking and in vitro anticancer screening of synthesized arylthiazole linked 2H-indol-2-one derivatives as VEGFR-2 kinase inhibitors. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), (2022), 22, 2166-2180.
• Pal, M.J. Akhtar, K. Raj, S. Singh, P. Sharma, S. Kalra, P.A. Chawla, B. Kumar Design, synthesis and evaluation of piperazine clubbed 1, 2, 4-triazine derivatives as potent anticonvulsant agents. Journal of Molecular Structure, (2022), 1257, 132587.
• Kusuma, S. Arora, S. Kalra, A. Chaturvedi, M. Heuser, R. Kumar, Rationalization of the activity profile of pyruvate kinase isozyme m2 (pkm2) inhibitors using 3D QSAR. Current Topics in Medicinal Chemistry, (2021), 21, 2258-2271
• Kumar, R.R. Kumar, S. Pathania, P.K. Singh, S. Kalra, B. Kumar, Investigation of indole functionalized pyrazoles and oxadiazoles as anti-inflammatory agents: synthesis, in-vivo, in-vitro and in-silico analysis. Bioorganic Chemistry, (2021), 105068(I.F.= 5.275) (accepted)
• Joshi, M. Sharma, S. Kalra, N. S. Gavande, S. Singh, R. Kumar, Design, Synthesis, Biological Evaluation of 3,5-diaryl-4,5-dihydro-1H-pyrazole carbaldehydes as Nonpurine Xanthine Oxidase Inhibitors: Tracing the Anticancer Mechanism via Xanthine Oxidase Inhibition. Bioorganic Chemistry, (2021), 104620 (I.F.= 5.275) (accepted)
• Dhaundiyal, P. Kumari, S. S. Jawalekar, G. Chauhan, S. Kalra#, U. Navik#, Is highly expressed ACE 2 in pregnant women “a curse” in times of COVID-19 pandemic?. Life Sciences, 264, (2020), 118676 (I.F.=5.037)
• Kumar, G. Chauhan, S. Kalra*, B. Kumar#, M. S. Gill#, A Perspective on Potential Target Proteins of COVID-19: Comparison with SARS-CoV for Designing New Small Molecules. Bioorganic Chemistry, 104, (2020), 104326 (I.F.= 5.275)
• Kalra, G. Joshi, M. Kumar, S. Arora, H. Kaur, S. Singh, A. Munshi, R. Kumar,Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanism via epidermal growth factor receptor (EGFR) inhibition. RSC Medicinal Chemistry, 11, (2020), 923-939 (I.F.= pending)
• Chauhan, M.J. Madou, S. Kalra, V. Chopra, D. Ghosh, S.O. Martinez-Chapa Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano, 14, (2020), 7760-7782 (I.F.= 15.881)
• S. Mishra, S. Ranjan, C.S. Sharma, H.P. Singh, S. Kalra, N. Kumar, Computational investigation of potential inhibitors of novel coronavirus 2019 through structure-based virtual screening, molecular dynamics and density functional theory studies. Journal of Biomolecular Structure and Dynamics, (2020) 1-13 (I.F.= 3.320)
• Kumar, S. Sharma, S. Kalra, G. Singh, V.D. Monga, B. Kumar, Medicinal Perspective of Indole Derivatives: Recent Developments and Structure-Activity Relationship Studies. Current Drug Targets, 21, (2020), 864-891 (I.F.= 3.465)
• Joshi, S. Kalra, U.P. Yadav, P. Sharma, P.K. Singh, S. Amutkar, A.J. Ansari, S. Kumar, A. Sharon, S. Sharma, D.M. Sawant, U.C. Banarjee, S. Singh, R. Kumar, Epharmacophore guided discovery of pyrazolo[1,5-c]quinazolines as dual inhibitors of topoisomerase-I and histone deacetylase. Bioorganic chemistry, 94, (2020), 103409 (I.F.= 5.275)
• J. Ansari, G. Joshi, U.P. Yadav, A.K. Maurya, V.K. Agnihotri, S. Kalra, R. Kumar, Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo [1, 5-c] quinazolines as potential EGFR inhibitors. Bioorganic chemistry, 93, (2019), 103314 (I.F.= 5.275)
• Narang, R. Kumar, S. Kalra, S.K. Nayak, G.L. Khatik, G.N. Kumar, Recent advancements in mechanistic studies and structure activity relationship of FoF1 ATP synthase inhibitor as antimicrobial agent. European journal of medicinal chemistry, 142, (2019), 111644 (I.F.= 6.514)
• S. Shekhar, T. Venkatachalam, C.S. Sharma, H. P. Singh, S. Kalra, Computational investigation of binding mechanism of substituted pyrazinones targeting corticotrophin releasing factor-1 receptor deliberated for anti-depressant drug design. Journal of Biomolecular Structure and Dynamics 37 (12), (2019), 3226-3244 (I.F.= 3.340)
• Chokkar*, S. Kalra*, Monica Chauhan, and Raj Kumar, A review on quinoline derived scaffolds as Anti-HIV Agents. Mini Reviews in Medicinal Chemistry, 19 (6), (2019), 510-526 (I.F.= 3.862)
• Chawla, S. Kalra, R. Kumar, R. Singh, S.K. Saraf, Novel 2-(substituted phenyl Imino)-5-benzylidene-4-thiazolidinones as possible non-ulcerogenic tri-action drug candidates: synthesis, characterization, biological evaluation And docking studies. Medicinal Chemistry Research 28 (3), (2019), 340-359 (I.F.= 1.965)
• Arora, G. Joshi, S. Kalra, A.A. Wani, P.V. Bharatam, P. Kumar, R. Kumar, Knoevenagel/Tandem Knoevenagel and Michael Adducts of Cyclohexane-1, 3-dione and Aryl Aldehydes: Synthesis, DFT Studies, Xanthine Oxidase Inhibitory Potential, and Molecular Modeling. ACS Omega 4 (3),(2019) 4604-4614 (I.F.= 3.512)
• Sharma, G. Joshi, S. Kalra, S. Singh, R. Kumar, Synthetic versus Enzymatic Pictet Spengler Reaction: An Overview, Current Organic Synthesis, 15 (7), (2018), 924- 939 (I.F. = 1.975)
• Kalra, R. Gill, A. Lundiach, G. Shafi, R. Vashistha, R. Kumar and A. Munshi Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: Results of Global Screening Array, European Journal of Clinical Pharmacology, 74 (10), (2018), 1291-1298 (I.F. = 2.953)
• Chokkar*, S. Kalra*, M. Chauhan, A. Munshi and R. Kumar, ” Quinoline-based protein–protein interaction inhibitors of LEDGF/p75 and HIV integrase: An in silico study”, Current topics in Medicinal Chemistry, 18 (32), (2018), 2800-2815 (I.F. =3.295)
• Kalra, G. Joshi, R. Kumar, A. Munshi, “Role of 2-Dimensional autocorrelation descriptors in predicting Antimalarial Activity of Artemisinin and its analogues: A QSAR study” Current topics in Medicinal Chemistry, 18 (31), (2018), 2720-2730 (I.F. =3.295)
• Kaur, R. P. Cholia, G. Joshi, S. M. Amrutkar, S. Kalra, A. K. Mantha, U. C. Banerjee, R. Kumar, Anticancer activity of dihydropyrazolo [1, 5-c] quinazolines against rat C6 glioma cells via inhibition of topoisomerase II Archiv der Pharmazie, 351 (6) (2018),1800023 (I.F.= 3.751)
• Kumar, G. Joshi, H. Kler, S. Kalra, M. Kaur, R. Arya, Toward an Understanding of Structural Insights of Xanthine and Aldehyde Oxidases: An Overview of their Inhibitors and Role in Various Diseases, Medicinal Research Reviews, 38 (4), (2018), 1073-1125. (I.F.= 12.944)
• M. Sawant, S. Sharma, R.S. Pathare, G. Joshi, S. Kalra, S. Sukanya, A. K. Maurya,R.K. Metre, V. K. Agnihotri, S. Khan, R. Kumar, R.T. Pardasani, Relay tricyclic Pd (ii)/Ag (i) catalysis: design of a four-component reaction driven by nitrene- transfer on isocyanide yields inhibitors of EGFR. Chemical Communications, 54(82), (2018), 11530- 11533 (I.F.= 6.222)
• Kumar, S.S. Mishra, C.S. Sharma, H.P. Singh, S. Kalra, In silico binding mechanism prediction of benzimidazole based corticotropin releasing factor-1 receptor antagonists by Quantitative structure activity relationship, molecular docking and pharmacokinetic parameters calculation, Journal of Biomolecular Structure and Dynamics, 36(7), (2018), 1691-1712. (I.F.= 3.340)
• Kalra, G. Joshi, A Munshi, R Kumar, Structural Insights of Cyclin Dependent Kinases: Implications in Design of Selective Inhibitors, European Journal of Medicinal Chemistry, 142, (2017), 424-458. (I.F. = 6.514)
• S. Usmani, G. Bedi, J.S. Samuel, S. Singh, S. Kalra, P. Kumar, A.A. Ahuja, M. Sharma, A. Gautam, G.P. Raghava, THPdb: Database of FDA-approved peptide and protein therapeutics, PloS One, 12, (2017), e0181748. (I.F. =3.24)
• Singla, S. Kalra, P. Kheterpal, V. Kumar, A. Munshi, Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy, Current cancer drug targets, 17, (2017), 344-356. (I.F. = 3.428)
• Joshi, H. Nayyar, S. Kalra, P. Sharma, A. Munshi, S. Singh, R. Kumar, Pyrimidine Containing Epidermal Growth Factor Receptor Kinase inhibitors: Synthesis and Biological Evaluation, Chemical Biology & Drug Design, 90(5), (2017), 995-1006 (I.F.=2.817)
• Chauhan, N. Gupta, D. Sehrawat, S. Kalra, G. Rath, A.K. Goyal, Albumin stabilized silver nanoparticles–clotrimazole β-cyclodextrin hybrid nanocomposite for enriched antifungal activity in normal and drug resistant Candida cells, RSC Advances,5(87), (2015),71190-71202 (I.F.= 3.361)
• Kalra, A. Kumar, M.K. Gupta, Modeling of Antitubercular Activity of Biphenyl analogues of 2-nitroimidazo[2,1-b][1,3]oxazine to Rationalize Their Activity Profile, Medicinal chemistry Research, 22, (2013), 3444-3451(I.F.= 1.965)
• Taxak, S. Kalra, P.V. Bharatam, Mechanism Based Inactivation of Cytochromes by Furan Epoxide: Unravelling the Molecular Mechanism. Inorganic Chemistry, 52 (23), (2013), 13496–13508 (I.F.=5.165)
• Kalra and P.V. Bharatam, Pharmacoinformatic tools in chemical regulations. CRIPS, 14 (1), (2013), 2-8

Book Chapter

• Interaction between topoisomerases and histone deacetylases: Role in cancer progression and therapeutic interventions

• 2023: Delivered an online Expert talk at ISFCP Dialogue Series-2023 on the topic “Overview to the Computer Aided Drug Design (CADD) Methodologies & Ongoing Research” on 3rd August 2023 held at ISF College of Pharmacy Moga 2023
• Attended FDP on “Instrumentation and Analytical techniques in Pharmaceutical Sciences” from 3rd July to 7th July 2023, held at Chitkara University, Himachal Pradesh
• 2020: Invited Speaker at AICTE sponsored training program (STTP) on “Target Based Drug Design Strategies Utilizing CADD Tools and Ecofriendly Microwave Assisted Green Synthesis” from 27 Apr – 2 May 2020, held at ISF College of Pharmacy, Moga, Punjab
• 2018: Attended 5 day Faculty Development Program (FDP) on “Applications of Tools in Pharmaceutical Education and Research” from 18-22 Dec 2018, held at ISF College of Pharmacy, Moga, Punjab
• 2018: Participated in workshop on “Analysis of Genome Scale Data from Bulk and Single-Cell Sequencing” from 19-23 Nov 2018, held at National Institute of Biomedical Genomics, Kalyani, W.B.
• 2017: Oral Presentation Award at APTI sponsored conference on “Emerging Trends in Computer Aided Drug Design & Drug Delivery” on 11 May 2017 held at Baddi University of Emerging Sciences and Technologies, Baddi, H.P.
• 2013: Presented poster on “Modeling of antitubercular activity of biphenyl analogs of 2-nitroimidazo[2,1-b][1,3]oxazine to rationalize their activity profile” at 7th Chandigarh Science Congress held at Panjab University, Chandigarh
• 2013: Delegate in 5th International Symposium on Drug Metabolism and Pharmacokinetics (DMPK) held at NIPER, Mohali
• 2013: Presented poster on “In silico dug receptor interactions study of various HIV- IN inhibitors and development of the docking model” at 3rd Indo-German conference at NIPER, Mohali
• 2013: Presented oral presentation at 16th Punjab Science congress held at Baba Farid University of Health Sciences, Faridkot
• 2011: Delegate in International Indo-Taiwan Workshop held at I.S.F. of College of Pharmacy, Moga
• 2011: Delegate in “Rational use and Clinical trial of Drugs” AICTE sponsored Seminar held at I.S.F. of College of Pharmacy, Moga
• 2011: Presented a poster in APTI (Association of Pharmaceutical Teachers) titled as, “HIV Integarse : A Live OR Dead Target for HIV” held at I.S.F. of College of Pharmacy, Moga
• 2010: Presented Poster “Synthesis and Biological evaluation Napthalene substituted Propiophenones and their derivatives as Potential cytotoxic agents” AICTE sponsored seminar held at Adesh Institute Of Medical Sciences, Bathinda
• 2009: Presented Poster “An account on Biological potential of synthetics derived from Meldrum’s acid” at Silver Jubilee Conference of IPGA (Indian Pharmacist Graduates Association) held at ISF College of Pharmacy, Moga.

FIELD OF SPECIALIZATION

• Computer aided drugs design, Synthesis and Biological

Project Completed

• SERB-SIRE FELLOW: In-silico methodologies in optimization of point of care technologies (Host Institute: Tecnológico de Monterrey); Funding Agency: SERB, Delhi, Funding amount: 20.05 lacs
• ICMR-Research Associate: Design, Synthesis and biological evaluation of purine derivatives as anticancer agents via CDK inhibition (Host Institute: NIPER, Mohali); Funding Agency: ICMR Delhi, Funding amount: 13.47 lacs

PROFESSIONAL MEMBERSHIPS AND RECOGNITIONS/AWARDS

Registered Pharmacist at Punjab State Pharmacy Council

• Ph.D. (DOCTOR OF PHILOSOPHY): Department of Human Genetics and Molecular Medicine from Central university of Punjab, Bathinda in May 2019
• M.PHARMACY: Passed with 66.3% from I.S.F. College of Pharmacy, Moga (Punjab Technical University, Jalandhar) in Oct 2012
• B.PHARMACY: Passed with 68% from I.S.F. College of Pharmacy, Moga (Punjab Technical University, Jalandhar) in 2010
• SENIOR SECONDARY (10+2): Passed with 68% from Sacred Heart School, Moga (ISC Delhi) in 2006.
• MATRICULATION: Passed with 68% from Sacred Heart School, Moga (ICSE Delhi) in 2004.

2.1 years Teaching Experience

8 Years Research Experience